CA2560282A1 - Forme cristalline d'hemi-calcium d'atorvastatine - Google Patents

Forme cristalline d'hemi-calcium d'atorvastatine Download PDF

Info

Publication number
CA2560282A1
CA2560282A1 CA002560282A CA2560282A CA2560282A1 CA 2560282 A1 CA2560282 A1 CA 2560282A1 CA 002560282 A CA002560282 A CA 002560282A CA 2560282 A CA2560282 A CA 2560282A CA 2560282 A1 CA2560282 A1 CA 2560282A1
Authority
CA
Canada
Prior art keywords
atorvastatin hemi
hemi calcium
calcium
atorvastatin
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002560282A
Other languages
English (en)
Inventor
Yatendra Kumar
Saridi Madhava Dileep Kumar
Swargam Sathyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CA2560282A1 publication Critical patent/CA2560282A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA002560282A 2004-03-17 2005-03-17 Forme cristalline d'hemi-calcium d'atorvastatine Abandoned CA2560282A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN491/DEL/2004 2004-03-17
IN491DE2004 2004-03-17
IN562/DEL/2005 2005-03-16
IN562DE2005 2005-03-16
PCT/IB2005/000687 WO2005090301A1 (fr) 2004-03-17 2005-03-17 Forme cristalline d'hemi-calcium d'atorvastatine

Publications (1)

Publication Number Publication Date
CA2560282A1 true CA2560282A1 (fr) 2005-09-29

Family

ID=34993618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002560282A Abandoned CA2560282A1 (fr) 2004-03-17 2005-03-17 Forme cristalline d'hemi-calcium d'atorvastatine

Country Status (4)

Country Link
EP (1) EP1761489A1 (fr)
AU (1) AU2005223491A1 (fr)
CA (1) CA2560282A1 (fr)
WO (1) WO2005090301A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875731B2 (en) * 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
CA2573771C (fr) 2004-07-20 2011-05-10 Warner-Lambert Company Llc Nouvelles formes de sel de calcium (2:1) d'acide [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
CA2582449A1 (fr) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Atorvastatine calcique amorphe
GB0613567D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
CN101268047B (zh) 2005-08-15 2012-11-07 箭锋国际有限公司 结晶和无定形阿托伐他汀钠
GB0613566D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
EP1928823B1 (fr) * 2005-08-15 2014-10-08 Arrow International Limited Procédé pour préparer un sel de sodium d'ATORVASTATINE cristallin
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
JP2010520273A (ja) * 2007-03-02 2010-06-10 ドン・ア・ファーム・カンパニー・リミテッド ピロリルヘプタン酸誘導体の新規な結晶形態
EP2075246A1 (fr) 2007-12-27 2009-07-01 M. J. Institute of Research Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
WO2009090544A2 (fr) * 2008-01-16 2009-07-23 Matrix Laboratories Limited Procédé de production d'atorvastatine calcique amorphe

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
PL365312A1 (en) * 2000-12-27 2004-12-27 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
KR100609371B1 (ko) * 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
PL368647A1 (en) * 2001-07-30 2005-04-04 Dr.Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium

Also Published As

Publication number Publication date
EP1761489A1 (fr) 2007-03-14
AU2005223491A1 (en) 2005-09-29
WO2005090301B1 (fr) 2005-12-01
WO2005090301A1 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
EP1727795B1 (fr) Procede de production d'atorvastatine calcique sous forme amorphe
CA2560282A1 (fr) Forme cristalline d'hemi-calcium d'atorvastatine
US20090216029A1 (en) Process for the production of atorvastatin calcium in amorphous form
WO2013179300A2 (fr) Procédé de préparation de vildagliptine et de son intermédiaire
US9139527B2 (en) Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof
EP2172452A1 (fr) Préparation de magnésium d'atorvastanine cristalline
EP1732886B1 (fr) Polymorphes d'ester de tert-butyle d'atorvastatine et leur utilisation en tant qu'intermediaires dans la preparation d'atorvastatine
WO2017060885A1 (fr) Procédé amélioré pour la préparation d'atorvastatine ou de sels pharmaceutiquement acceptables de celle-ci
CA2578722C (fr) Processus pour calcium d'atorvastatine amorphe
EP2057151A2 (fr) Procédé de purification d'aprépitant
EP2075246A1 (fr) Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
WO2007052296A2 (fr) Procede de preparation de calcium d'atorvastatine amorphe
US20040242670A1 (en) Process for preparation of amorphous atorvastatin calcium
WO2006001026A1 (fr) Polymorphes d'irbesartan
WO2006011155A1 (fr) Procede en enceinte unique pour calcium d'atorvastatine amorphe
EP2373609A1 (fr) Utilisation de composés amphiphiles pour la cristallisation régulée de statines et d'intermédiaires de statines
WO2008053312A2 (fr) Procédé de préparation d'un sel d'hémicalcium d'atorvastatine amorphe et intermédiaire de ce dernier
WO2005033078A1 (fr) Procede de production d'atorvastatine calcique
WO2004069819A1 (fr) Nouvelle forme de simvastatine

Legal Events

Date Code Title Description
FZDE Dead